The impact of introducing tyrosine kinase inhibitors on chronic myeloid leukemia survival: a population-based study

The impact of introducing tyrosine kinase inhibitors on chronic myeloid leukemia survival: a population-based study

Abstract Background Chronic myeloid leukemia is associated with a BCR/ABL oncoprotein inhibited by imatinib mesylate, the first tyrosine kinase inhibitor. Although experimental studies have clearly demonstrated the efficacy of imatinib, up-to-date data on its effectiveness at the population level ar...

Full description

Bibliographic Details
Main Authors: Enza Di Felice, Francesca Roncaglia, Francesco Venturelli, Lucia Mangone, Stefano Luminari, Claudia Cirilli, Giuliano Carrozzi, Paolo Giorgi Rossi
Format: Article
Language:English
Published: BMC 2018-11-01
Series:BMC Cancer
Subjects:
Chronic myeloid leukemia
Imatinib Mesylate
Survival analysis
Population registers
Interrupted time series analysis
Online Access:http://link.springer.com/article/10.1186/s12885-018-4984-3

Internet

http://link.springer.com/article/10.1186/s12885-018-4984-3

Similar Items